JPWO2020074461A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020074461A5
JPWO2020074461A5 JP2021543577A JP2021543577A JPWO2020074461A5 JP WO2020074461 A5 JPWO2020074461 A5 JP WO2020074461A5 JP 2021543577 A JP2021543577 A JP 2021543577A JP 2021543577 A JP2021543577 A JP 2021543577A JP WO2020074461 A5 JPWO2020074461 A5 JP WO2020074461A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutical composition
hydrogen
compound according
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021543577A
Other languages
Japanese (ja)
Other versions
JP7383030B2 (en
JP2022514799A (en
Publication date
Priority claimed from GBGB1816369.1A external-priority patent/GB201816369D0/en
Application filed filed Critical
Publication of JP2022514799A publication Critical patent/JP2022514799A/en
Publication of JPWO2020074461A5 publication Critical patent/JPWO2020074461A5/ja
Application granted granted Critical
Publication of JP7383030B2 publication Critical patent/JP7383030B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (15)

式（１）：
Figure 2020074461000001
を有するかまたはその塩もしくは互変異性体である化合物であって、Ｒ１が水素またはフッ素である、化合物。 Formula (1):
Figure 2020074461000001
or a salt or tautomer thereof, wherein R 1 is hydrogen or fluorine. 請求項１に記載の化合物であって、Ｒ１が水素であり、前記化合物が式（２）：
Figure 2020074461000002
を有するかまたはその塩もしくは互変異性体である、化合物。 2. The compound of claim 1, wherein R1 is hydrogen and said compound has the formula (2):
Figure 2020074461000002
or a salt or tautomer thereof. 請求項１に記載の化合物であって、Ｒ１がフッ素であり、前記化合物が式（３）：
Figure 2020074461000003
を有するかまたはその塩もしくは互変異性体である、化合物。 2. The compound of claim 1, wherein R1 is fluorine and said compound has formula (3):
Figure 2020074461000003
or a salt or tautomer thereof. 非塩形態である、請求項１～３のいずれか一項に記載の化合物。 A compound according to any one of claims 1 to 3, in non-salt form. 医薬における使用のための、請求項１～４のいずれか一項に記載の化合物を含む医薬組成物。 A pharmaceutical composition comprising a compound according to any one of claims 1-4 for use in medicine. ＴＹＫ２阻害剤としての使用のための、請求項１～４のいずれか一項に記載の化合物を含む医薬組成物。 A pharmaceutical composition comprising a compound according to any one of claims 1-4 for use as a TYK2 inhibitor. 炎症性障害または免疫障害の処置のための、請求項１～４のいずれか一項に記載の化合物を含む医薬組成物。 A pharmaceutical composition comprising a compound according to any one of claims 1-4 for the treatment of inflammatory or immune disorders. 自己免疫疾患の処置のための、請求項１～４のいずれか一項に記載の化合物を含む医薬組成物。 A pharmaceutical composition comprising a compound according to any one of claims 1-4 for the treatment of autoimmune diseases. ＴＹＫ２キナーゼに対する活性を有する化合物を用いた処置に感受性のあるであろう疾患または容態に罹患しているかまたは罹患している危険にあるものとしてスクリーニンおよび決定された患者における疾患状態または容態の処置または予防のための、請求項１～４のいずれか一項に記載の化合物を含む、医薬組成物。Treatment of disease states or conditions in patients screened for and determined as having or at risk of having a disease or condition that would be susceptible to treatment with a compound having activity against TYK2 kinase or a pharmaceutical composition comprising a compound according to any one of claims 1-4 for prophylaxis. 前記化合物がさらなる治療薬と組み合わせて使用される、請求項５～９のいずれか一項に記載の医薬組成物。A pharmaceutical composition according to any one of claims 5-9, wherein said compound is used in combination with an additional therapeutic agent. 請求項１～４のいずれか一項に記載の化合物と医薬として許容され得る賦形剤とを含む、医薬組成物。 A pharmaceutical composition comprising a compound according to any one of claims 1-4 and a pharmaceutically acceptable excipient. 式（１５）：Formula (15):
Figure 2020074461000004
Figure 2020074461000004
の化合物の加水分解を含む、請求項１～４のいずれか一項に記載の化合物の調製のための方法であって、式中、Ｒ A process for the preparation of a compound according to any one of claims 1 to 4, comprising hydrolysis of a compound of R １1 が、酸性条件の下で水素またはフッ素である、方法。is hydrogen or fluorine under acidic conditions. ＲR. １1 が水素である、請求項１２に記載の方法。13. The method of claim 12, wherein is hydrogen. 式（１５）：Formula (15):
Figure 2020074461000005
Figure 2020074461000005
の化合物であって、式中、Ｒwherein R １1 が水素またはフッ素である、化合物。is hydrogen or fluorine. ＲR. １1 が水素である、請求項１４に記載の化合物。15. The compound of claim 14, wherein is hydrogen.
JP2021543577A 2018-10-08 2019-10-07 TYK2 kinase inhibitor Active JP7383030B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1816369.1 2018-10-08
GBGB1816369.1A GB201816369D0 (en) 2018-10-08 2018-10-08 Pharmaceutical compounds
PCT/EP2019/077118 WO2020074461A1 (en) 2018-10-08 2019-10-07 Tyk2 kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2022514799A JP2022514799A (en) 2022-02-15
JPWO2020074461A5 true JPWO2020074461A5 (en) 2022-09-28
JP7383030B2 JP7383030B2 (en) 2023-11-17

Family

ID=64397425

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021543577A Active JP7383030B2 (en) 2018-10-08 2019-10-07 TYK2 kinase inhibitor

Country Status (13)

Country Link
US (1) US20210387981A1 (en)
EP (1) EP3864009A1 (en)
JP (1) JP7383030B2 (en)
KR (1) KR20210076036A (en)
CN (1) CN113056456B (en)
AU (1) AU2019359320B2 (en)
BR (1) BR112021006424A2 (en)
CA (1) CA3111049A1 (en)
GB (1) GB201816369D0 (en)
IL (1) IL281599B1 (en)
MX (1) MX2021003929A (en)
SG (1) SG11202102490TA (en)
WO (1) WO2020074461A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202005114D0 (en) * 2020-04-07 2020-05-20 Sareum Ltd Crystalline Forms of a Pharmaceutical Compound
WO2023076161A1 (en) 2021-10-25 2023-05-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0709031D0 (en) * 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
AU2008266883B2 (en) 2007-06-20 2014-01-30 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
US8278335B2 (en) 2008-04-21 2012-10-02 Merck Sharp & Dohme Corp. Inhibitors of Janus kinases
CA2727928A1 (en) 2008-06-18 2009-12-23 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
JP2011527680A (en) 2008-07-09 2011-11-04 メルク・シャープ・エンド・ドーム・コーポレイション JANUS kinase inhibitors
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
US20130096104A1 (en) 2010-03-17 2013-04-18 Genentech, Inc. Imidazopyridine compounds, compositions and methods of use
WO2012000970A1 (en) 2010-07-01 2012-01-05 Cellzome Limited Triazolopyridines as tyk2 inhibitors
US20130231340A1 (en) * 2012-03-02 2013-09-05 Sareum Limited Pharmaceutical compounds
KR101202026B1 (en) 2012-07-03 2012-11-16 민호현 Method for manufacturing loess stone-planting
TWI605041B (en) 2012-11-08 2017-11-11 必治妥美雅史谷比公司 Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifnα responses
CN105793245B (en) * 2013-09-03 2018-03-20 萨勒姆有限公司 Medical compounds
NO2721710T3 (en) 2014-08-21 2018-03-31
GB201617871D0 (en) 2016-10-21 2016-12-07 Sareum Limited Pharmaceutical compounds

Similar Documents

Publication Publication Date Title
JP2023002662A5 (en)
JP2020033360A5 (en)
JP2017528507A5 (en)
CA2705294C (en) Methods of treating arthritis by the administration of substituted benzenesulfonamides
JP2018513107A5 (en)
JP2022191257A5 (en)
JP2017528503A5 (en)
JP2009510044A5 (en)
JP2013544887A5 (en)
JP2023116697A5 (en)
JP2008542290A (en) Methods and compositions for using 4-[(cyclopropanecarbonylamino) methyl] -2- (2,6-dioxopiperidin-3-yl) isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
JPWO2020074461A5 (en)
JP5341037B2 (en) Use of agomelatin to obtain a medicament for treating bipolar disorder
JP2019516722A (en) Use of a carbamate compound for the purpose of preventing or treating trigeminal neuralgia
JP7016880B2 (en) Myopia prophylaxis, myopia treatment and / or myopia progression inhibitor containing tiotropium as an active ingredient
WO2017148129A1 (en) Pharmaceutical composition for treating cachexia and use thereof
JP2015520759A5 (en)
JP4380967B2 (en) Preventive or therapeutic agent for viral myocarditis
BR112012000410B1 (en) use of benzidamine or acid addition salts, and, pharmaceutical composition
JPWO2019232130A5 (en)
JP2021505691A5 (en)
JP2015189677A (en) Pharmaceutical composition comprising solifenacin amorphous body
JPWO2020178721A5 (en)
JPWO2019210511A5 (en)
TW201808285A (en) Compositions and methods for treating anxiety disorders